We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Aparna Ramasubramanian MD

Aparna Ramasubramanian MD

Director, Retinoblastoma Program, Phoenix Children’s Hospital, Phoenix, Arizona

Dr. Aparna Ramasubramanian is the medical director of the Phoenix Children's retinoblastoma program. An expert in the field of ocular oncology in the United States, Dr. Ramasubramanian has very unique training as a dual fellowship-trained physician in both pediatric ophthalmology and ocular oncology. Since coming to Phoenix Children's, Dr. Ramasubramanian has significantly grown the multidisciplinary program. She treats patients from not only from Arizona and the Southwest, but also children and families from across the country who travel to Phoenix Children's for their ongoing specialty care. Dr. Ramasubramanian is the author of the leading textbook on retinoblastoma and the program developer for the `Cure Retinoblastoma' campaign run by the Children's Eye Foundation. She received the American Academy of Ophthalmology Achievement Award in 2018 and the Knights Templar Research Award for her research in retinoblastoma.

Recent Contributions to PracticeUpdate:

  1. Current Management Strategies for Patients With Uveal Melanoma
  2. Emerging Concepts in the Genetics, Global Disease Burden, Chemotherapy Outcomes, and Psychological Impact of Retinoblastoma
  3. Blood Neutrophil-to-Lymphocyte Ratio as a Risk Factor in the Treatment of Retinopathy of Prematurity
  4. Effects of Fetal Haemoglobin on Systemic Oxygenation in Preterm Infants and the Development of Retinopathy of Prematurity
  5. Prenatal Maternal Characteristics Associated With Retinopathy of Prematurity Development in Infants
  6. Refractive Status, Biometric Components, and Functional Outcomes in Patients With Threshold Retinopathy of Prematurity
  7. 2022 Top Story in Eye Care: Bevacizumab in the Treatment of Retinopathy of Prematurity
  8. Prevalence and Risk Factors of Hypothalamus–Pituitary–Adrenal Axis Suppression in Infants Receiving Glucocorticoid Eye Drops After Ocular Surgery
  9. Outcomes of Low-Dose vs Very Low–Dose Bevacizumab Treatment in Infants With Retinopathy of Prematurity
  10. Childhood Amblyopia: Importance of Detecting Early

Most Read This Week

Recently Updated